Divalproex Sodium Tablet, Delayed Release
Product Images NDC 71335-2158

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71335-2158). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
A bar chart comparing the percentage outcomes of placebo (PBO) versus divalproex sodium delayed-release tablets (DVPX) in two studies, labeled Study 1 (YMRS) and Study 2 (MRS). The chart shows higher percentages for DVPX (60% and 58%) compared to placebo (26% and 29%) in both studies, with an asterisk indicating statistical significance (p < 0.05).*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
A line graph comparing the percentage reduction in CPS rate among patients taking Divalproex Sodium Delayed-Release Tablets versus those taking placebo. The x-axis represents the percentage of patients, while the y-axis shows the percent reduction in CPS rate, indicating improvement or worsening.*
FDA Label Image

Figure 3 (Divalproex Fig3)

Figure 3 (Divalproex Fig3)
A line graph labeled Figure 3 showing the percentage reduction in CRS rate on the vertical axis versus the percentage of patients on the horizontal axis. Two lines indicate the effects of high dose (solid line) and low dose (dashed line) treatments, with improvement and worsening marked directionally.*
FDA Label Image

Figure 4 (Divalproex Fig4)

Figure 4 (Divalproex Fig4)
A bar chart titled 'Mean 4-week Migraine Rates' comparing migraine frequency between placebo and Divalproex Sodium delayed-release tablets in two studies. The vertical axis measures migraine rates from 0 to 6. Study 1 and Study 2 each show lower migraine rates with Divalproex Sodium compared to placebo, with dosage notes provided below the chart.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)
Chemical structure diagram of divalproex sodium showing its molecular arrangement, with organic chains and sodium ion clearly depicted.*
FDA Label Image

Label (Lbl713352158)

Label (Lbl713352158)
Divalproex Sodium DR 500 mg delayed-release tablet label by Bryant Ranch Prepack. The label indicates comparison to Depakote 500 mg tablet by Aurobindo Pharma Limited. It highlights storage instructions at 20°-25°C (68°-77°F), includes a lot number, barcode, and NDC 71335-2158, with a quantity of 60 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.